Kongressthemen This is the primary industry platform dedicated to providing you insight into the latest clinical results and stimulating discussions around
how to take cytokine-based immunotherapy combinations forward.
The renewed interest in the anti-tumor properties of cytokines has led to an increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs.
Speakers: Ruth Ganss, Professor in Translational Cancer Research, Harry Perkins Institute of Medical Research, University of Western Australia, and more.
Kongressgebühr Digital Conference Only - Drug Developer Pricing: USD 1999.00,
Digital Conference Only - Service Provider Pricing: USD 2499.00,
Digital Conference Only - Academic Pricing: USD 1799.00
Teilnehmer erwartet 1000 - 1000
Veranstalter Kontakt 83 Great Titchfield Street W1W 6RH London Großbritannien